Mice that are homozygous for the targeted mutation are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. No expression of the targeted gene's protein product is detected on the cell surface, as determined by flow cytometry analysis of splenocytes from homozygotes. Mutants exhibit a reduction in recirculating mature B cells in the bone marrow and fewer transitional B cells in the spleen. Splenic and peripheral B cells express lower levels of membrane bound IgM than wildtype. B cell activation is abnormal in mutant mice, with enhanced Ca2+ mobilization after stimulation. Lipopolysaccaharide (LPS) challenge results in an increased proliferative response. CD22 deficient B cells have a shorter than average lifespan when compared to wildtype B cells. T-cell independent immune responses are impaired. This mutant mouse strain may be useful in studies of glycosidic molecular interactions and function, B cell development and T cell independent immune response.
This strain was transferred from the collection of the Consortium for Functional Glycomics.

Use of MICE only available to non-profit entities.

CD22 deficient mutant mice exhibit a reduction in recirculating mature B cells in the bone marrow and fewer transitional B cells in the spleen. Splenic and peripheral B cells express lower levels of membrane bound IgM than wildtype. B cell activation is abnormal in mutant mice, with enhanced Ca2+ mobilization after stimulation. This mutant mouse strain may be useful in studies of glycosidic molecular interactions and function, B cell development and T cell independent immune response.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.